Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2019
SIETES contiene 92854 citas

 
 
 1 a 20 de 89 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]
2.Tiene citas relacionadas Cita con resumen
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017;390:8 de julio. [Ref.ID 101669]
3.Tiene citas relacionadas Cita con resumen
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016;387:2093-105. [Ref.ID 100313]
4.Tiene citas relacionadas Cita con resumen
Moore N, Salvo F, Duong M, Gulmez SE. Does paracetamol still have a future in osteoarthritis?. Lancet 2016;387:2065-6. [Ref.ID 100312]
5.Enlace a cita original Cita con resumen
Lipworth BJ, Williamson PA. ß blockers for asthma: a double-edge sword. Lancet 2009;373:104-5. [Ref.ID 84959]
6.Tiene citas relacionadas Cita con resumen
Garjón Parra J, Imizcoz MA, Amézqueta Goñi C. Antiinflamatorios no esteroideos y riesgo cardiovascular. Boletín de Información Farmacoterapéutica de Navarra 2008;16:77-87. [Ref.ID 84887]
8.Tiene citas relacionadas Cita con resumen
Dargie HJ. ß blockers in heart failure. Lancet 2003;362:2-3. [Ref.ID 66290]
9.
Khan AA, Brahim JS, Rowan J S, Dionne RA. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther 2002;72:44-9. [Ref.ID 62758]
10.
Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000;356:1373-4. [Ref.ID 53600]
11. Cita con resumen
Swan SK, Rudy D W, Lasseter KC, Ryan C F, Buechel K L, Lambrecht LJ, Pinto M B, Dilzer SC, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater C, Yao SL. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000;133:1-9. [Ref.ID 51703]
13.
Powis D. Select medical students. BMJ 1998;317:1149-50. [Ref.ID 41441]
14.
Goldbeck-Wood S. Choosing tomorrow's doctors. BMJ 1996;313:313. [Ref.ID 28865]
15.
Van Bortel LMAB, Ament AJHA. Selective versus nonselective ß adrenoceptor antagonists in hypertension. Pharmacoeconomics 1995;8:513-23. [Ref.ID 25351]
16. Cita con resumen
Rolfe I E, Pearson S, Powis D A, Smith AJ. Time for a review of admission to medical school?. Lancet 1995;346:1329-33. [Ref.ID 25310]
17. Cita con resumen
Brown MJ. To ß block or better block?. BMJ 1995;311:701-2. [Ref.ID 24831]
18.
Ito K, Yajima N, Ohtani H, Yamada Y, Nakamura K, Sawada Y, Iga T. Prediction of the therapeutic dose for ß-stimulants based on preclinical data: application of oral dosage forms and aerosols to asthmatic patients. J Pharmacokinet Biopharm 1992;21:133-44. [Ref.ID 20344]
19.
Murray M, Reidy G F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 1990;42:85-101. [Ref.ID 15434]
20.
Reguero S, Blanco A, Lapeña S. Evaluación del primer año de selectividad en la Facultad de Medicina de Valladolid (curso 1977-78). Med Clin (Barc) 1991;96:141-5. [Ref.ID 14074]
Seleccionar todas
 
 1 a 20 de 89 siguiente >>